3-June-2019: The global blockbuster oncology brands market is
poised to reach USD 62.80 billion by 2027, according to a new report by Grand
View Research, Inc., progressing at a CAGR of 7.3% during the forecast period.
Shift towards immunotherapies coupled with increasing number of indication
expansion trials is one of the primary growth stimulants for the market.
Current market analysis reveals
Revlimid and Opdivo as bestselling therapies in the marketplace in 2017.
However, a robust pipeline will uplift Opdivo’s sales, while Revlimid’s patent
expiration will lower its revenue share in the market by 2027. Although Keytruda
poses strong competition to Opdivo, especially after bagging a frontline
approval for NSCLC in 2017, the immunotherapeutic is expected to trail behind
the latter by 2027.
Lifecycle management
strategies, including expansion of approved indications and development of
combination therapies, underline competitive dynamics in the global blockbuster
oncology brands market. Collaborative agreements signed by participating
companies facilitate development, commercialization, and regional expansion of
products. Such strategies not only enable players to gain easy access into new
markets, but also allow them to leverage scientific and technological expertise
of their collaborative partner.
In
depth research report on Blockbuster Oncology Brands Market
Further
key findings from the report suggest:
· North
America dominated the global arena in 2017, with approximately 65.0% share. The
region is likely to maintain its position through 2027
· In
terms of revenue, the lung cancer segment is estimated to expand at a CAGR of
over 9.0% during the forecast period
· The
multiple myeloma segment held more than 30.0% of the market revenue in 2017 and
is anticipated to lose its position to lung cancer by 2027
· Europe
is projected to experience modest growth during the forecast period due to
delays in cost-effectiveness analysis, carried out by health technology
assessment bodies, slowing approval process and lowering reimbursement
· Some of
the key companies present in the market are Tesaro, Inc.; Merck &Co.;
Bristol Myers Squibb; AstraZeneca Plc; and Roche Ltd.
Grand View Research has
segmented the global blockbuster oncology brands market on the basis of brands,
indication, and region:
Blockbuster
Oncology Brands Outlook (Revenue, USD Million, 2015 - 2027)
· Opdivo
· Keytruda
· Perjeta
· Ibrance
· Tecentriq
· Gazyva
· Zejula
· Tagrisso
· Darzalex
· Imbruvica
· Revlimid
Blockbuster
Oncology Brands Indication Outlook (Revenue, USD Million, 2015 - 2027)
· Lung
cancer
· Breast
cancer
· Multiple
myeloma
· Lymphoma
· Others
Browse
more research reports of this category:
About
Grand View Research
Grand View Research, Inc. is a
U.S. based market research and consulting company, registered in the State of
California and headquartered in San Francisco. The company provides syndicated
research reports, customized research reports, and consulting services. To help
clients make informed business decisions, the company offers market
intelligence studies ensuring relevant and fact-based research across a range
of industries including technology, chemicals, materials, healthcare and
energy.
No comments:
Post a Comment